SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Speculation that SK Hynix may use Intel Foundry for next-generation HBM base dies is driving attention, alongside broader enthusiasm over AI-chip demand and possible future foundry partnerships. Traders are split between viewing a confirmed customer deal as a potential turnaround catalyst and cautioning that the report only says SK Hynix is considering the relationship, while Intel Foundry remains unprofitable.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The approaching 80th death event in SELLASs Phase 3 REGAL AML trial is driving attention, with the official count still reported at 78 of 80 and traders debating whether the prolonged event accrual signals durable GPS benefit. Bullish participants point to long patient survival and supportive comments attributed to pharmaceutical professionals, while skeptics cite potential censoring, control-arm assumptions, trial-design concerns and the binary risk of the final readout.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

A rebound in Bitcoin and broader crypto markets, alongside traders reports of strong Robinhood Chain activity and growing crypto and prediction-market volumes, is driving attention to HOOD. The community is broadly bullish on potential transaction-revenue growth, though some traders are taking profits or questioning the stocks repeated resistance and sharp volatility.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Strong quarterly results, improved same-store sales, and raised full-year guidance are fueling renewed optimism that CEO Brian Niccols turnaround is gaining traction. Traders remain divided over whether the recovery is fully priced in, citing Starbucks premium valuation, margin concerns, and ongoing consumer and competitive pressures.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of municipal WiFi into Helium carrier coverage, along with broader Helium Mobile and carrier adoption, is driving attention and bullish interest in HNT. Traders are debating whether the move reflects expanding real-world utility and DePIN momentum or a speculative rally vulnerable to token dilution, weak hotspot economics, and management concerns.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Positive Phase 3 Voyage results for DT120 in generalized anxiety disorder, which met its primary and key secondary endpoints, are driving attention and reinforcing expectations for a potential NDA after the Panorama readout. Traders remain broadly bullish on the drugs multi-indication potential, though some argue the results were priced in and cite remission rates, lengthy monitored sessions, dilution, and valuation concerns behind the sell-the-news reaction.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Geopolitical tensions involving Iran, oil and potential market weakness have traders watching UVXY for a volatility spike, but its muted response has fueled debate. Some traders allege VIX suppression or manipulation, while others attribute the divergence to UVXYs VIX-futures exposure, contango and structural decay rather than spot-market volatility.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

A better-than-expected fiscal third-quarter earnings report, driven by resilient parks and improving streaming profitability, alongside reaffirmed growth guidance and increased buybacks, has renewed interest in Disney. Traders are split between a bullish turnaround and breakout thesis and concerns over the revenue shortfall, persistent resistance, and the risk that the earnings pop fades.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Reported discussions around Chevron expanding its Venezuelan oil operations are driving attention, with traders viewing the company as a potential beneficiary of closer U.S.-Venezuela energy ties and additional production. The community remains divided, as skeptics question the timing, infrastructure constraints, and political uncertainty surrounding any deal.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

Regulatory uncertainty surrounding Hapag-Lloyds proposed acquisitionincluding Israeli national-security concerns and a reported Brazilian antitrust reviewhas kept ZIM in focus, with traders debating whether the deal will close, be delayed, or give way to a competing bid. Bullish investors are emphasizing strong container freight rates, cash generation and future dividends, while skeptics point to the absent quarterly dividend and takeover risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03...

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and six months ended June 30, 2026. The second...

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with...

Why Is Turn Therapeutics Stock Trading Higher Today?

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.read more...

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the...

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its...

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled...

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the...

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief...

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M...

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded by Bradley Burnam on January 6, 2015 and is headquartered in Westlake Village, CA.

Turn Therapeutics Inc.

Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$9.84
Prev Close	$10.11
Open	$10.10
Dividend Yield	0.00%
50-Day Moving Average	$8.80
Beta	1.45
Avg. Volume	128,285.55
PE Ratio	-34.19

52-Week High	$26.50
52-Week Low	$2.57
Market Capitalization	$293.11M
EPS (Annual)	-$0.1152
Price to Book	426.71
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info